Mashiko Setshedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mashiko Setshedi has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Suzanne M. de la Monte
Departments of Pathology and Laboratory Medicine, Neurology, Neurosurgery, and Medicine, Rhode Island Hospital, Brown University Health, Alpert Medical School of Brown University, United States
6 shared publications Jack R. Wands
Divisions of Gastroenterology and Neuropathology, Departments of Medicine, Pathology, Neurology, and Neurosurgery, The Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
5 shared publications- Jake Ej Krige
University of Cape Town
4 shared publications Lisa Longato
Division of Gastroenterology, Department of Medicine, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
4 shared publications- Stella Ifeanyi Smith
Molecular Biology and Biotechnology Department Nigerian Institute of Medical Research Lagos Nigeria
3 shared publications - Abbas Yadegar
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- 1 September 2026
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 64 (3) , 337-342
Diagnostic yield and appropriate use of an upper endoscopy service in a resource-constrained setting
- 1 September 2026
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 64 (3) , 337-342
Diagnostic yield and appropriate use of an upper endoscopy service in a resource-constrained setting
- 1 September 2026
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 64 (3) , 310-316
Predictors of intermediate and long-term survival in gastric variceal bleeding
- 1 September 2026
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 64 (3) , 310-316
Predictors of intermediate and long-term survival in gastric variceal bleeding
- 17 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (3) , 308-312
Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real‐World Practice
Background: Despite increasingly refined diagnostic strategies and regularly updated treatment guidelines, real‐world outcomes of Helicobacter pylori management remain variable. Antimicrobial resistance alone does not fully explain these discrepancies, suggesting important challenges in the implementation of evidence‐based care. Aims: To identify recurring implementation‐related challenges across the Helicobacter pylori care pathway and highlight priorities for improving real‐world management. Methods: This expert‐informed review integrated relevant literature, international guideline documents, and structured international expert prioritisation. An initial list of implementation‐related pitfalls was developed through literature review, clinical experience, and discussions among the coordinating authors and selected co‐authors. Twenty‐six experts from five continents participated in a structured consultation process and rated predefined pitfalls using a 5‐point Likert scale. Median scores were used for relative prioritisation. Results: Treatment selection and patient management emerged as the domains most consistently prioritised by participating experts. High‐impact pitfalls included empirical triple therapy in high‐resistance settings, inadequate patient counselling, and empirical retreatment without escalation. Additional challenges were identified across diagnostic, treatment, and follow‐up domains, highlighting persistent implementation‐related barriers throughout the care pathway. Conclusions: Recurring implementation‐related challenges remain important barriers to optimal Helicobacter pylori management. Structured expert prioritisation highlights potential targets for improvement and supports further research and implementation‐focused strategies to improve delivery of care.
- 17 June 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (3) , 308-312
Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real‐World Practice
Background: Despite increasingly refined diagnostic strategies and regularly updated treatment guidelines, real‐world outcomes of Helicobacter pylori management remain variable. Antimicrobial resistance alone does not fully explain these discrepancies, suggesting important challenges in the implementation of evidence‐based care. Aims: To identify recurring implementation‐related challenges across the Helicobacter pylori care pathway and highlight priorities for improving real‐world management. Methods: This expert‐informed review integrated relevant literature, international guideline documents, and structured international expert prioritisation. An initial list of implementation‐related pitfalls was developed through literature review, clinical experience, and discussions among the coordinating authors and selected co‐authors. Twenty‐six experts from five continents participated in a structured consultation process and rated predefined pitfalls using a 5‐point Likert scale. Median scores were used for relative prioritisation. Results: Treatment selection and patient management emerged as the domains most consistently prioritised by participating experts. High‐impact pitfalls included empirical triple therapy in high‐resistance settings, inadequate patient counselling, and empirical retreatment without escalation. Additional challenges were identified across diagnostic, treatment, and follow‐up domains, highlighting persistent implementation‐related barriers throughout the care pathway. Conclusions: Recurring implementation‐related challenges remain important barriers to optimal Helicobacter pylori management. Structured expert prioritisation highlights potential targets for improvement and supports further research and implementation‐focused strategies to improve delivery of care.
- 1 May 2026
- Published by Medpharm Publications in South African Journal of Gastroenterology and Hepatology
- Vol. 3 (1) , 18-21
Update on Helicobacter pylori infection: the state of antimicrobial resistance in Africa
- 1 May 2026
- Published by Medpharm Publications in South African Journal of Gastroenterology and Hepatology
- Vol. 3 (1) , 18-21
Update on Helicobacter pylori infection: the state of antimicrobial resistance in Africa
- Open Access
- 8 December 2025
- Published by Taylor & Francis in South African Journal of Clinical Nutrition
- Vol. 39 (1) , 34-41
Size does matter: clinical outcomes of percutaneous endoscopic gastrostomy (PEG) placement in a South African tertiary endoscopy unit
- 8 December 2025
- Published by Taylor & Francis in South African Journal of Clinical Nutrition
- Vol. 39 (1) , 34-41
Open AccessSize does matter: clinical outcomes of percutaneous endoscopic gastrostomy (PEG) placement in a South African tertiary endoscopy unit
- 1 September 2025
- Published by Medpharm Publications in South African Journal of Gastroenterology and Hepatology
- Vol. 2 (2) , 83-87
Small bowel capsule endoscopy for obscure gastrointestinal bleeding not associated with a reduction in iron or haemoglobin support
- 1 September 2025
- Published by Medpharm Publications in South African Journal of Gastroenterology and Hepatology
- Vol. 2 (2) , 83-87
Small bowel capsule endoscopy for obscure gastrointestinal bleeding not associated with a reduction in iron or haemoglobin support
- Top Cited Papers
Helicobacter pylori antibiotic resistance: a global challenge in search of solutions
Background: Helicobacter pylori resistance to antibiotics commonly used in eradication regimens is increasing dramatically in many locations; new strategies are needed to manage this infectious disease. Objective: This study’s aim was to collect and update information on antibiotic resistance (AR) rates in H. pylori as well as current strategies for H. pylori management, including public health issues, from a global perspective. Design: An international survey was conducted in 31 countries on 6 continents to address key issues concerning the management of H. pylori -related AR. Individual aspects included the prevalence of AR for specific antibiotics, antibiotic susceptibility testing (AST) in different healthcare systems, availability of drugs, reimbursement issues and strategies for H. pylori AR surveillance. Results: Resistance to the most effective antibiotics used in H. pylori eradication regimens is increasing globally, with clarithromycin and levofloxacin resistance exceeding 15% in 24/31 and 18/31 countries, respectively. Amoxicillin remains an exception, with resistance rates under 2% in 14/31 countries; though African countries have reported amoxicillin resistance rates of over 90%. Bismuth-based treatment regimens are the most effective and are recommended as first-line treatment in several countries. However, more than 1 billion inhabitants worldwide have no access to bismuth-based regimens. PCR-based tests for AR are used in 16/26 countries but are reimbursed in only 4, while next generation sequencing-based tests are available, but not reimbursed, in 3 countries. In 22/26 countries only culture-based methods are available (reimbursed in 9/26 countries). AR surveillance programmes have only been established in 4/26 countries. Therefore, in most countries, empirical therapy with the most effective local regimen available locally is practiced. Conclusion: The dramatic global rise in H. pylori antibiotic resistance requires an urgent revision of current management strategies. Possible solutions include AST-based selection of effective treatment regimens, identification of novel combinations of existing drugs and exploration of novel drugs.
Top Cited PapersHelicobacter pylori antibiotic resistance: a global challenge in search of solutions
Background: Helicobacter pylori resistance to antibiotics commonly used in eradication regimens is increasing dramatically in many locations; new strategies are needed to manage this infectious disease. Objective: This study’s aim was to collect and update information on antibiotic resistance (AR) rates in H. pylori as well as current strategies for H. pylori management, including public health issues, from a global perspective. Design: An international survey was conducted in 31 countries on 6 continents to address key issues concerning the management of H. pylori -related AR. Individual aspects included the prevalence of AR for specific antibiotics, antibiotic susceptibility testing (AST) in different healthcare systems, availability of drugs, reimbursement issues and strategies for H. pylori AR surveillance. Results: Resistance to the most effective antibiotics used in H. pylori eradication regimens is increasing globally, with clarithromycin and levofloxacin resistance exceeding 15% in 24/31 and 18/31 countries, respectively. Amoxicillin remains an exception, with resistance rates under 2% in 14/31 countries; though African countries have reported amoxicillin resistance rates of over 90%. Bismuth-based treatment regimens are the most effective and are recommended as first-line treatment in several countries. However, more than 1 billion inhabitants worldwide have no access to bismuth-based regimens. PCR-based tests for AR are used in 16/26 countries but are reimbursed in only 4, while next generation sequencing-based tests are available, but not reimbursed, in 3 countries. In 22/26 countries only culture-based methods are available (reimbursed in 9/26 countries). AR surveillance programmes have only been established in 4/26 countries. Therefore, in most countries, empirical therapy with the most effective local regimen available locally is practiced. Conclusion: The dramatic global rise in H. pylori antibiotic resistance requires an urgent revision of current management strategies. Possible solutions include AST-based selection of effective treatment regimens, identification of novel combinations of existing drugs and exploration of novel drugs.
- 13 November 2024
- Published by Wiley in Helicobacter
- Vol. 29 (6) , e13153
Helicobacter pylori Management in Africa: A Survey of Diagnostic, Treatment, and Related Resources
Background: Although Helicobacter pylori infection (H. pylori) prevalence in Africa has declined in the last decade, it remains concerningly high. H. pylori is asymptomatic in the majority of patients but is associated with significant morbidity and mortality in 10%–20%.Materials and Methods: We conducted an online survey of 21 African countries, with the link distributed to members of the African Helicobacter Microbiota Study Group. The survey was completed by 562 respondents; the majority were from Nigeria (27.2%), South Africa (18.1%), Tanzania (17.6%), Egypt (16.9%), and Cameroon (14.2%).Results: The most common reason for H. pylori testing was dyspepsia in 83.9% of the cases. Abnormal findings at gastroscopy (62.3%) and heartburn (61.7%) were also common indications. Stool antigen testing and histological examination of gastric biopsies using Giemsa were the two most used methods for H. pylori testing at 62.3% and 50.3%, respectively. Most respondents reported the use of standard clarithromycin‐based triple therapy as first‐line treatment for H. pylori infection.Conclusion: This survey has demonstrated the diversity of practice and resource availability within the African continent. Several international guidelines exist on the management of H. pylori, but little data is available in Africa on how this condition is managed in every day clinical practice. There is an urgent need to formulate evidence‐based and locally relevant practice guidelines on the African continent. In this context, the African Helicobacter and Microbiota study group was formed to coordinate efforts across the continent on H. pylori research to provide guidance on its management. This paper, therefore, aimed to evaluate the practice of H. pylori diagnostics and management, as well as related resources in representative countries in Africa, to facilitate the development of such guidelines.
- 13 November 2024
- Published by Wiley in Helicobacter
- Vol. 29 (6) , e13153
Helicobacter pylori Management in Africa: A Survey of Diagnostic, Treatment, and Related Resources
Background: Although Helicobacter pylori infection (H. pylori) prevalence in Africa has declined in the last decade, it remains concerningly high. H. pylori is asymptomatic in the majority of patients but is associated with significant morbidity and mortality in 10%–20%.Materials and Methods: We conducted an online survey of 21 African countries, with the link distributed to members of the African Helicobacter Microbiota Study Group. The survey was completed by 562 respondents; the majority were from Nigeria (27.2%), South Africa (18.1%), Tanzania (17.6%), Egypt (16.9%), and Cameroon (14.2%).Results: The most common reason for H. pylori testing was dyspepsia in 83.9% of the cases. Abnormal findings at gastroscopy (62.3%) and heartburn (61.7%) were also common indications. Stool antigen testing and histological examination of gastric biopsies using Giemsa were the two most used methods for H. pylori testing at 62.3% and 50.3%, respectively. Most respondents reported the use of standard clarithromycin‐based triple therapy as first‐line treatment for H. pylori infection.Conclusion: This survey has demonstrated the diversity of practice and resource availability within the African continent. Several international guidelines exist on the management of H. pylori, but little data is available in Africa on how this condition is managed in every day clinical practice. There is an urgent need to formulate evidence‐based and locally relevant practice guidelines on the African continent. In this context, the African Helicobacter and Microbiota study group was formed to coordinate efforts across the continent on H. pylori research to provide guidance on its management. This paper, therefore, aimed to evaluate the practice of H. pylori diagnostics and management, as well as related resources in representative countries in Africa, to facilitate the development of such guidelines.
- 1 June 2024
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 62 (2) , 161-168
Intermediate and long-term survival prediction using prognostic scores in patients undergoing salvage TIPS for uncontrolled variceal bleeding
Background: This study investigated the value of prognostic scores to predict 90-day, 1-, 3- and 5-year survival after salvage TIPS (sTIPS) in patients with exsanguinating variceal bleeding who failed endoscopic intervention. Methods: The Model for End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease Sodium (MELDNa), Acute Physiology and Chronic Health Evaluation II (APACHE II) and Child-Pugh (C-P) grades and scores were calculated using Kaplan-Meier curves and Cox proportional hazards models in sTIPS patients treated between August 1991 and November 2020. Results: Thirty-four patients (29 men, 5 women), mean age 52 years, SD +/- 11.6 underwent sTIPS which controlled bleeding in 32 (94%) patients. Ten (29.4%) patients died in hospital at a median of 4.8 (range 1-10) days. On bivariate analysis, C-P score >= 10 (p p = 0.017), high C-P grade (p p = 0.048), MELD >= 15 (p p = 0.010), MELD-Na score >= 22 (p p < 0.001) and APACHE II score >= 15 (p p < 0.001) predicted 90-day mortality. Individual clinical characteristics associated with 90-day mortality were grade 3 ascites (p p = 0.029), > 10 units of blood transfused (p p = 0.004), balloon tube placement (p p < 0.001), endotracheal intubation (< 0.001) and inotrope support (p p < 0.001). The overall 90-day, 1-, 3- and 5-year survival rates were 67.6%, 55.9%, 26.5% and 20.6% respectively. Nine patients (26.5%) were alive at a median of two years (range 1-18 years) post-TIPS. Patients with C-P grade A, C-P score < 10, MELD score < 15, MELD-Na score < 22 and APACHE II score < 15 had significantly better 90-day, 1-, 3- and 5-year survival rates. Conclusion: Although sTIPS controlled variceal bleeding in 94% of patients after failed endoscopic therapy, in-hospital mortality was 29% and less than one quarter were alive after five years. The selected cut-off values for the nominated scoring systems accurately predicted 90-day mortality and long-term survival.
- 1 June 2024
- Published by Medpharm Publications in South African Journal of Surgery
- Vol. 62 (2) , 161-168
Intermediate and long-term survival prediction using prognostic scores in patients undergoing salvage TIPS for uncontrolled variceal bleeding
Background: This study investigated the value of prognostic scores to predict 90-day, 1-, 3- and 5-year survival after salvage TIPS (sTIPS) in patients with exsanguinating variceal bleeding who failed endoscopic intervention. Methods: The Model for End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease Sodium (MELDNa), Acute Physiology and Chronic Health Evaluation II (APACHE II) and Child-Pugh (C-P) grades and scores were calculated using Kaplan-Meier curves and Cox proportional hazards models in sTIPS patients treated between August 1991 and November 2020. Results: Thirty-four patients (29 men, 5 women), mean age 52 years, SD +/- 11.6 underwent sTIPS which controlled bleeding in 32 (94%) patients. Ten (29.4%) patients died in hospital at a median of 4.8 (range 1-10) days. On bivariate analysis, C-P score >= 10 (p p = 0.017), high C-P grade (p p = 0.048), MELD >= 15 (p p = 0.010), MELD-Na score >= 22 (p p < 0.001) and APACHE II score >= 15 (p p < 0.001) predicted 90-day mortality. Individual clinical characteristics associated with 90-day mortality were grade 3 ascites (p p = 0.029), > 10 units of blood transfused (p p = 0.004), balloon tube placement (p p < 0.001), endotracheal intubation (< 0.001) and inotrope support (p p < 0.001). The overall 90-day, 1-, 3- and 5-year survival rates were 67.6%, 55.9%, 26.5% and 20.6% respectively. Nine patients (26.5%) were alive at a median of two years (range 1-18 years) post-TIPS. Patients with C-P grade A, C-P score < 10, MELD score < 15, MELD-Na score < 22 and APACHE II score < 15 had significantly better 90-day, 1-, 3- and 5-year survival rates. Conclusion: Although sTIPS controlled variceal bleeding in 94% of patients after failed endoscopic therapy, in-hospital mortality was 29% and less than one quarter were alive after five years. The selected cut-off values for the nominated scoring systems accurately predicted 90-day mortality and long-term survival.
- Open Access
- 26 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (6) , 969
Helicobacter pylori Infection: Antibiotic Resistance and Solutions for Effective Management in Africa
Helicobacter pylori (H. pylori) infection is ubiquitous worldwide, with prevalence rates of greater than 70% in Africa. Symptomatic patients present with foregut gastrointestinal symptoms which can be readily diagnosed with standardized non-invasive or invasive tests. The biggest challenge, however, is in the management of this condition with rising antimicrobial resistance rates to most of the antibiotics recommended for therapy. This is a problem worldwide, but more specifically in Africa, where the socio-economic and political climate is such that eradication of this organism seems impossible. Furthermore, the recommended antimicrobial susceptibility testing for drug resistance is not widely available in Africa due to the lack of infrastructural as well as human resources. With the widespread unregulated use of antibiotics in some parts of Africa, the figures of antimicrobial resistance are likely to soar. In the face of these significant challenges, this ‘perspectives’ article aims to address the issue of antimicrobial resistance in Africa, by providing achievable and targeted goals to curb the spread of infection and rising antimicrobial resistance.
- 26 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (6) , 969
Open AccessHelicobacter pylori Infection: Antibiotic Resistance and Solutions for Effective Management in Africa
Helicobacter pylori (H. pylori) infection is ubiquitous worldwide, with prevalence rates of greater than 70% in Africa. Symptomatic patients present with foregut gastrointestinal symptoms which can be readily diagnosed with standardized non-invasive or invasive tests. The biggest challenge, however, is in the management of this condition with rising antimicrobial resistance rates to most of the antibiotics recommended for therapy. This is a problem worldwide, but more specifically in Africa, where the socio-economic and political climate is such that eradication of this organism seems impossible. Furthermore, the recommended antimicrobial susceptibility testing for drug resistance is not widely available in Africa due to the lack of infrastructural as well as human resources. With the widespread unregulated use of antibiotics in some parts of Africa, the figures of antimicrobial resistance are likely to soar. In the face of these significant challenges, this ‘perspectives’ article aims to address the issue of antimicrobial resistance in Africa, by providing achievable and targeted goals to curb the spread of infection and rising antimicrobial resistance.